title: Endothelial nitric oxide synthase gene polymorphism (Glu298Asp) in patients with coexistent hypertrophic cardiomyopathy and coronary spastic angina.
abstract: Coronary vasospasm appears to play a significant role in the etiology of myocardial ischemia in patients with hypertrophic cardiomyopathy (HCM). Furthermore, the management of patients with coexistent HCM and coronary spastic angina (CSA) presents a therapeutic challenge. The purpose of this study was to examine the Glu298Asp variant of the endothelial nitric oxide synthase (eNOS) gene to determine whether this polymorphism was associated with susceptibility to CSA in patients with HCM. The eNOS gene polymorphism (Glu298Asp) was genotyped in 150 HCM patients by the TaqMan chemical method. Patients were classified into group A (n=12) if they had CSA provoked by intracoronary acetylcholine, and group B (n=138) if they did not. In group A, the frequency of Glu/Glu, Glu/Asp, and Asp/Asp genotypes was 5 (41.7%), 6 (50%), and 1 (8.3%), respectively. In group B, it was 119 (86.2%), 17 (12.3%), and 2 (1.5%), respectively. The frequency of the Asp298 variant was significantly higher in group A than in group B (P<0.001). Multivariate logistic regression analysis showed that the Asp298 variant was a significant risk factor for CSA (odds ratio 11.8; P<0.001) that was independent of age, gender, smoking status or body mass index. Significantly more drugs were used by the patients in group A than those in group B and the patients with the Asp298 variant were treated with significantly more drugs than those without it. In conclusion, the Asp298 variant of the eNOS gene may be associated with CSA in HCM patients. HCM patients with CSA or the Asp298 variant may need more drugs to relieve their symptoms.
authors.affiliation: The Second Department of Internal Medicine, Ehime University School of Medicine, Shitsukawa, Toon, Ehime, 791-0295 Japan. aogimoto@m.ehime-u.ac.jp
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Ogimoto
authors.forename: Yuji
authors.initials: Y
authors.lastname: Shigematsu
authors.forename: Jun
authors.initials: J
authors.lastname: Nakura
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hara
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Ohtsuka
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Kohara
authors.forename: Mareomi
authors.initials: M
authors.lastname: Hamada
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Miki
authors.forename: Jitsuo
authors.initials: J
authors.lastname: Higaki
mesh_terms: D019943:Amino Acid Substitution; D000787:Angina Pectoris / Q000150:complications / Q000235:genetics*; D001224:Aspartic Acid / Q000235:genetics*; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications / Q000235:genetics*; D005260:Female; D005973:Glutamine / Q000235:genetics*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D052250:Nitric Oxide Synthase Type III / Q000235:genetics*; D011110:Polymorphism, Genetic; D012307:Risk Factors
chemical_list: D005973:Glutamine; D001224:Aspartic Acid; D052250:Nitric Oxide Synthase Type III